Home / Resource Library / Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study

Results of a study investigating mosunetuzumab with polatuzumab for treatment of relapsed MCL.